PL3917626T3 - Dwutrybowy radioznacznik i terapeutyk wiążący psma - Google Patents

Dwutrybowy radioznacznik i terapeutyk wiążący psma

Info

Publication number
PL3917626T3
PL3917626T3 PL20702636.0T PL20702636T PL3917626T3 PL 3917626 T3 PL3917626 T3 PL 3917626T3 PL 20702636 T PL20702636 T PL 20702636T PL 3917626 T3 PL3917626 T3 PL 3917626T3
Authority
PL
Poland
Prior art keywords
radiotractor
psma
dual
mode
binding therapeutic
Prior art date
Application number
PL20702636.0T
Other languages
English (en)
Inventor
Alexander Josef WURZER
Hans-Jürgen Wester
Matthias Johannes EIBER
Original Assignee
Technische Universität München
Technische Universität München - Klinikum Rechts Der Isar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technische Universität München, Technische Universität München - Klinikum Rechts Der Isar filed Critical Technische Universität München
Publication of PL3917626T3 publication Critical patent/PL3917626T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008Peptides; Proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0404Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0497Organic compounds conjugates with a carrier being an organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Circuits Of Receivers In General (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Nuclear Medicine (AREA)
  • Toys (AREA)
  • Electrotherapy Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL20702636.0T 2019-01-30 2020-01-30 Dwutrybowy radioznacznik i terapeutyk wiążący psma PL3917626T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19154500 2019-01-30
PCT/EP2020/052248 WO2020157177A1 (en) 2019-01-30 2020-01-30 Psma binding dual mode radiotracer and therapeutic

Publications (1)

Publication Number Publication Date
PL3917626T3 true PL3917626T3 (pl) 2023-11-27

Family

ID=65268810

Family Applications (2)

Application Number Title Priority Date Filing Date
PL20702636.0T PL3917626T3 (pl) 2019-01-30 2020-01-30 Dwutrybowy radioznacznik i terapeutyk wiążący psma
PL23167668.5T PL4249456T3 (pl) 2019-01-30 2020-01-30 Radioznacznik i środek terapeutyczny wiążący psma o podwójnym działaniu

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL23167668.5T PL4249456T3 (pl) 2019-01-30 2020-01-30 Radioznacznik i środek terapeutyczny wiążący psma o podwójnym działaniu

Country Status (19)

Country Link
US (2) US12357711B2 (pl)
EP (2) EP4249456B1 (pl)
JP (2) JP7528100B2 (pl)
KR (1) KR102850587B1 (pl)
CN (2) CN113677400B (pl)
AU (2) AU2020213678B2 (pl)
BR (1) BR112021014933A2 (pl)
CA (1) CA3128401A1 (pl)
DK (2) DK3917626T3 (pl)
EA (1) EA202191691A1 (pl)
ES (2) ES2953196T3 (pl)
FI (2) FI3917626T3 (pl)
HU (2) HUE069264T2 (pl)
IL (2) IL303421A (pl)
MX (1) MX2021008999A (pl)
PL (2) PL3917626T3 (pl)
PT (2) PT3917626T (pl)
SG (1) SG11202108109RA (pl)
WO (1) WO2020157177A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11413360B2 (en) 2017-07-28 2022-08-16 Technische Universität München Dual mode radiotracer and—therapeutics
ES2953196T3 (es) * 2019-01-30 2023-11-08 Univ Muenchen Tech Radiotrazador de modo dual de unión a PSMA y terapéutico
GB202005282D0 (en) 2020-04-09 2020-05-27 Blue Earth Diagnostics Ltd Pharmaceutical Formulations
BR112023000763A2 (pt) * 2020-07-13 2023-03-21 Point Biopharma Inc Composição farmacêutica, método para preparar 177lu-psma i&t, método para tratar um paciente, complexo, método para tratar um indivíduo
US20230277698A1 (en) * 2020-07-23 2023-09-07 Technische Universität München Silicon-containing ligand compounds
EP4023250A1 (en) * 2021-01-04 2022-07-06 Technische Universität München Dual mode radiotracer and -therapeutics
JP2024507343A (ja) * 2021-02-15 2024-02-19 テクニシェ ユニバーシタット ミュンヘン デュアルモード放射性トレーサーおよびその療法
GB202109922D0 (en) 2021-07-09 2021-08-25 Blue Earth Diagnostics Ltd Radiotracers and therapeutics binding to fibroblast activation protein (fap)
GB202113646D0 (en) 2021-09-24 2021-11-10 Blue Earth Diagnostics Ltd Method of preparation of 18F labelled silyl-fluoride compounds
WO2023056221A1 (en) * 2021-09-28 2023-04-06 Antelope Surgical Solutions, Inc. Multifunctional compounds for use in medical imaging and therapy
GB202207372D0 (en) 2022-05-19 2022-07-06 Blue Earth Diagnostics Ltd Synthesis of fluorosilyl compounds
GB202316239D0 (en) 2023-10-24 2023-12-06 Blue Earth Diagnostics Ltd Therapeutic combination
GB202318958D0 (en) * 2023-12-12 2024-01-24 King S College London Compound

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2097111B1 (en) * 2006-11-08 2015-07-15 Molecular Insight Pharmaceuticals, Inc. Heterodimers of glutamic acid
SG191338A1 (en) 2010-12-22 2013-07-31 Ge Healthcare Ltd Her2 binding peptides labelled with a 18f - containing organosilicon compound
CN102626522B (zh) 2012-04-12 2014-09-10 韩彦江 基于趋化因子受体cxcr4多肽类拮抗剂的多肽放射性诊断与治疗药物
GEP20237479B (en) * 2013-10-18 2023-03-27 Deutsches Krebsforsch Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
WO2016062370A1 (en) 2014-10-20 2016-04-28 Deutsches Krebsforschungszentrum 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
CN117563022A (zh) * 2017-04-05 2024-02-20 康奈尔大学 可用于成像和抗肿瘤治疗的具有可调的药代动力学的三功能构建体
US11413360B2 (en) 2017-07-28 2022-08-16 Technische Universität München Dual mode radiotracer and—therapeutics
IL319022A (en) * 2017-12-11 2025-04-01 Univ Muenchen Tech PSMA imaging and endoradiotherapy ligands
ES2953196T3 (es) 2019-01-30 2023-11-08 Univ Muenchen Tech Radiotrazador de modo dual de unión a PSMA y terapéutico

Also Published As

Publication number Publication date
AU2023203501A1 (en) 2023-07-06
KR20210153037A (ko) 2021-12-16
AU2023203501B2 (en) 2024-11-14
CN113677400A (zh) 2021-11-19
WO2020157177A1 (en) 2020-08-06
EP4249456A2 (en) 2023-09-27
FI3917626T3 (fi) 2023-08-17
CN113677400B (zh) 2023-12-01
US20250295819A1 (en) 2025-09-25
DK4249456T3 (da) 2024-12-02
JP7763885B2 (ja) 2025-11-04
IL303421A (en) 2023-08-01
PL4249456T3 (pl) 2025-03-31
PT3917626T (pt) 2023-08-23
AU2020213678B2 (en) 2024-05-30
EP4249456B1 (en) 2024-09-04
FI4249456T3 (fi) 2024-12-07
BR112021014933A2 (pt) 2021-10-05
US20220096668A1 (en) 2022-03-31
CN116675730A (zh) 2023-09-01
EP3917626A1 (en) 2021-12-08
ES2953196T3 (es) 2023-11-08
KR102850587B1 (ko) 2025-08-27
HUE063038T2 (hu) 2023-12-28
JP2022523727A (ja) 2022-04-26
HUE069264T2 (hu) 2025-02-28
MX2021008999A (es) 2021-11-04
CA3128401A1 (en) 2020-08-06
ES2995872T3 (en) 2025-02-11
EA202191691A1 (ru) 2021-11-01
AU2020213678A1 (en) 2021-08-12
IL284958A (en) 2021-09-30
EP3917626B1 (en) 2023-05-31
JP2024073651A (ja) 2024-05-29
SG11202108109RA (en) 2021-08-30
DK3917626T3 (da) 2023-08-28
US12357711B2 (en) 2025-07-15
EP4249456A3 (en) 2023-10-11
IL284958B1 (en) 2026-01-01
PT4249456T (pt) 2024-12-02
JP7528100B2 (ja) 2024-08-05

Similar Documents

Publication Publication Date Title
PL3917626T3 (pl) Dwutrybowy radioznacznik i terapeutyk wiążący psma
DK3947375T3 (da) Imidazolonylquinolinforbindelser og terapeutiske anvendelser deraf
EP3920763A4 (en) SKIN CARE DEVICES
KR102199943B9 (ko) 의료용 자극 장치
JP1662410S (ja) 患者インターフェース
EP3802802A4 (en) CELLULAR THERAPY
JP1655460S (ja) ポータブルチェアー
IL291486A (en) Therapeutic conjugates
EP3735463A4 (en) Cytotoxicity-inducing therapeutic agent
EP4003475C0 (en) PATIENT INTERFACE
EP3999156A4 (en) PATIENT INTERFACE
EP3781576C0 (en) BORONIC ACID DERIVATIVES AND THEIR THERAPEUTIC USES
EP3946535A4 (en) PATIENT INTERFACE
EP3741296A4 (en) BIOELECTRODE
IL283900A (en) Pharmaceutical combinations
EP4013440A4 (en) THERAPEUTIC PEPTIDES
EP4028096A4 (en) Patient interface
EP3986419A4 (en) Boronic acid derivatives and therapeutic uses thereof
EP3764973A4 (en) ENTERIC SOFT ENVELOPE CAPSULES
EP3962528A4 (en) Therapeutic combinations comprising anti-cd123 immunoconjugates
EP3927328A4 (en) INHALABLE THERAPEUTIC AGENT
EP4169571C0 (en) THERAPY DEVICE
IL280968A (en) Combination therapy
EP4007553C0 (en) MIRROR THERAPY DEVICE
EP4076381C0 (en) TRANSMUCOSAL THERAPEUTIC SYSTEM CONTAINING AGOMELATINE